Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1954 1
1955 4
1956 1
1957 2
1958 3
1959 2
1960 1
1961 3
1962 3
1963 5
1964 6
1965 8
1966 5
1967 6
1968 8
1969 12
1970 7
1971 12
1972 17
1973 23
1974 28
1975 20
1976 17
1977 19
1978 26
1979 19
1980 33
1981 23
1982 30
1983 35
1984 45
1985 56
1986 71
1987 75
1988 77
1989 105
1990 83
1991 80
1992 99
1993 67
1994 70
1995 86
1996 88
1997 115
1998 84
1999 90
2000 86
2001 104
2002 118
2003 103
2004 108
2005 124
2006 129
2007 137
2008 127
2009 147
2010 127
2011 128
2012 149
2013 132
2014 157
2015 172
2016 199
2017 253
2018 274
2019 279
2020 265
2021 301
2022 307
2023 273
2024 135
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

5,449 results

Results by year

Filters applied: . Clear all
Page 1
Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors.
Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T. Akiyama T, et al. Among authors: yamashita k. Cancer Res. 2023 Mar 2;83(5):753-770. doi: 10.1158/0008-5472.CAN-22-1890. Cancer Res. 2023. PMID: 36543251
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation.
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, Osa A, Machiyama H, Watanabe G, Sax N, Villa J, Kinugasa-Katayama Y, Nojima S, Yaga M, Hosono Y, Okuzaki D, Satoh S, Tsuda T, Nakanishi Y, Suga Y, Morita T, Fukushima K, Nishide M, Shiroyama T, Miyake K, Iwahori K, Hirata H, Nagatomo I, Yano Y, Tamiya M, Kumagai T, Takemoto N, Inohara H, Yamasaki S, Yamashita K, Aoshi T, Akbay EA, Hosen N, Shintani Y, Takamatsu H, Mori M, Takeda Y, Kumanogoh A. Naito Y, et al. Among authors: yamashita k. Sci Adv. 2023 May 19;9(20):eade0718. doi: 10.1126/sciadv.ade0718. Epub 2023 May 19. Sci Adv. 2023. PMID: 37205755 Free PMC article.
Paradigm shift in myocarditis treatment.
Yakhshimurodov U, Yamashita K, Kawamura T, Kawamura M, Miyagawa S. Yakhshimurodov U, et al. Among authors: yamashita k. J Cardiol. 2024 Mar;83(3):201-210. doi: 10.1016/j.jjcc.2023.08.009. Epub 2023 Aug 18. J Cardiol. 2024. PMID: 37597837 Review.
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kawashima A, Haruna M, Hirata M, Ueyama A, Iwahori K, Satoh T, Kurokawa Y, Eguchi H, Doki Y, Wada H. Nose Y, et al. Among authors: yamashita k. Cancer Immunol Immunother. 2023 Jan;72(1):169-181. doi: 10.1007/s00262-022-03240-2. Epub 2022 Jul 1. Cancer Immunol Immunother. 2023. PMID: 35776160 Free PMC article.
Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability.
Kamiya M, Matsumoto M, Yamashita K, Izumi T, Kawaguchi M, Mizukami S, Tsurumaru M, Mukai H, Kawakami S. Kamiya M, et al. Among authors: yamashita k. Pharmaceutics. 2022 Oct 31;14(11):2357. doi: 10.3390/pharmaceutics14112357. Pharmaceutics. 2022. PMID: 36365175 Free PMC article.
Therapeutic Advances in the Treatment of Gastroesophageal Cancers.
Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Li JJ, et al. Among authors: yamashita k. Biomolecules. 2023 May 6;13(5):796. doi: 10.3390/biom13050796. Biomolecules. 2023. PMID: 37238666 Free PMC article. Review.
Structure and engineering of the minimal type VI CRISPR-Cas13bt3.
Nakagawa R, Kannan S, Altae-Tran H, Takeda SN, Tomita A, Hirano H, Kusakizako T, Nishizawa T, Yamashita K, Zhang F, Nishimasu H, Nureki O. Nakagawa R, et al. Among authors: yamashita k. Mol Cell. 2022 Sep 1;82(17):3178-3192.e5. doi: 10.1016/j.molcel.2022.08.001. Epub 2022 Aug 25. Mol Cell. 2022. PMID: 36027912 Free PMC article.
Structural mobility tunes signalling of the GluA1 AMPA glutamate receptor.
Zhang D, Ivica J, Krieger JM, Ho H, Yamashita K, Stockwell I, Baradaran R, Cais O, Greger IH. Zhang D, et al. Among authors: yamashita k. Nature. 2023 Sep;621(7980):877-882. doi: 10.1038/s41586-023-06528-0. Epub 2023 Sep 13. Nature. 2023. PMID: 37704721 Free PMC article.
5,449 results